The document discusses three levels of decision making for healthcare resources - macro, intermediate, and micro. It finds that decision making is currently fragmented between these levels, with different decision makers not following common objectives or methods. There is also significant variation between countries. The document identifies some potential policy options to better align decision making across levels, including using a consistent value principle, strengthening intermediate-level decisions, and monitoring data on health and economic impacts. However, more research is needed to develop an integrated decision making framework to reduce inefficiencies in health systems from the misalignment between different decision-making levels.
Data Governance for Real-World Evidence: Cross-country differences and recommendations for a governance framework
Cole, A., Garrison, L., Mestre-Ferrandiz, J. & Towse A.
Data Governance for Real-World Evidence: Cross-country differences and recommendations for a governance framework
Cole, A., Garrison, L., Mestre-Ferrandiz, J. & Towse A.
Are Wider Societal Effects Considered in Healthcare Decision-making? An over...Office of Health Economics
Presentation at ISPOR Italy - 12.04.16 - Are Wider Societal Effects Considered in Healthcare Decision-making? An overview from other countries by Martina Garau, OHE
This project explored whether an aligned, forward-looking health technology assessment (HTA) process exists, or can be established. The areas of interest for modern HTA systems were identified and explored in terms of ‘future directions’, namely the HTA good practice principles that are debated or that pose implementation challenges. Based on conversations with HTA experts from high- and middle-income countries, we concluded that an aligned, modern, forward-looking HTA is not feasible but further research initiatives would be valuable to stimulate debate and provide clarity in these topic areas.
Author(s) and affiliation(s): Margherita Neri, the Office of Health Economics, Grace Hampson, the Office of Health Economics and Adrian Towse, the Office of Health Economics
Conference/meeting: ISPOR Europe 2018
Event location: Barcelona, Spain
Date: 13 November 2018
Adrian Towse's slides from a session will exploring how the benefits of antibiotics can best be captured in HTA, and how we should pay for them when their value may depend on restricting their use.
Author(s) and affiliation(s): Adrian Towse, Office of Health Economics
Conference/meeting: Health Technology Assessment International (HTAi) 2018
Location: Vancouver, Canada
Date: 03/06/2018
Are Wider Societal Effects Considered in Healthcare Decision-making? An over...Office of Health Economics
Presentation at ISPOR Italy - 12.04.16 - Are Wider Societal Effects Considered in Healthcare Decision-making? An overview from other countries by Martina Garau, OHE
This project explored whether an aligned, forward-looking health technology assessment (HTA) process exists, or can be established. The areas of interest for modern HTA systems were identified and explored in terms of ‘future directions’, namely the HTA good practice principles that are debated or that pose implementation challenges. Based on conversations with HTA experts from high- and middle-income countries, we concluded that an aligned, modern, forward-looking HTA is not feasible but further research initiatives would be valuable to stimulate debate and provide clarity in these topic areas.
Author(s) and affiliation(s): Margherita Neri, the Office of Health Economics, Grace Hampson, the Office of Health Economics and Adrian Towse, the Office of Health Economics
Conference/meeting: ISPOR Europe 2018
Event location: Barcelona, Spain
Date: 13 November 2018
Adrian Towse's slides from a session will exploring how the benefits of antibiotics can best be captured in HTA, and how we should pay for them when their value may depend on restricting their use.
Author(s) and affiliation(s): Adrian Towse, Office of Health Economics
Conference/meeting: Health Technology Assessment International (HTAi) 2018
Location: Vancouver, Canada
Date: 03/06/2018
Reflections on Implementing Value-based Assessment in the UK -- Towse at HESG Office of Health Economics
Value-based pricing, as originally proposed in the UK, was intended to achieve several objectives, including broadening the definition of value. This presentation reviews important issues in defining value, demonstrates how past policy aimed at value has affected the availability of some medicines, and suggests ways forward under the revised, value-based assessment approach.
Evidence on Improving Health Service Delivery in Developing CountriesIDS
This presentation by David Peters of the Future Health Systems Consortium was given at the Global Symposium on Health Systems Research in November 2010.
Health system strengthening – what is it, how should we assess it, and does i...ReBUILD for Resilience
This presentation was given to the UK's Department for International Development on 30th July 2019.
Comprehensive reviews of health system strengthening interventions are rare, partly because of lack of clarity on definitions of the term but also the potentially huge scale of the evidence. In our talk, we will reflect on the process of undertaking such an evidence review for DFID recently (attached again), drawing out suggestions on definitions of HSS and approaches to assessment, as well as summarising some key conclusions from the current evidence base. Most HSS interventions have theories of change relating to specific system blocks, but more work is needed on capturing their spill-over effects and their contribution to meeting over-arching health system process goals. We will make some initial suggestions about such goals, to reflect the features that characterise a ‘strong health system’. We will highlight current findings on ‘what works’ but also that these are just indicative, given the limitations and biases in what has been studied and how, and argue that there is need to re-think evaluation methods for HSS beyond finite interventions and narrow outcomes. Clearer concepts, frameworks and methods can support more coherent HSS investment.
> Why HEOR?
> Costs, Consequences and Perspectives
> Key Stakeholders in HEOR
> What is Health Economics and Pharmaco-economic Research?
> Economic Evaluations
> Incremental Cost Effectiveness Ratio (ICER)
> Concept of HRQoL
> Comparative Effectiveness Research (CER)
> Pragmatic Clinical Trials
> Observational Studies
> Systematic Reviews and Meta-Analysis
> Application of CER
> Health Technology Assessment (HTA)
> Real World Evidence (RWE)
> Patient Reported Outcomes (PROs)
> Patient Focused Drug Development (PFDD)
> Application of Health Economic Evaluations
> Challenges and Barriers
The National Health Council conducted research, did an analysis, and prepared proposed regulatory language to assist the Secretary of Health and Human Services with the preparation of an essential health benefits (EHB) package that will serve the needs of people with chronic diseases and disabilities. This slide show is from a NHC briefing on EHB, given August 3, 2011.
Health system strengthening evidence review – A summary of the 2021 updateReBUILD for Resilience
A presentation given by Professor Sophie Witter to the UK government's Foreign, Commonwealth & Development Office. This summarises a 2021 review of a health systems strengthening evidence review originally undertaken for the office in 2019.
HCM 3305, Community Health 1 Course Learning Outcom.docxaryan532920
HCM 3305, Community Health 1
Course Learning Outcomes for Unit VIII
Upon completion of this unit, students should be able to:
3. Recognize effective organization and promotion of health programming for community health on a
global scale.
3.1. Assess the steps for organizing a community health program.
3.2. Identify steps needed to effectively evaluate the community health program.
Reading Assignment
Chapter 15:
Systems Thinking and Leadership in Community and Public Health
Unit Lesson
In this unit, we will discuss systems thinking and community health programming.
Community organizing is a process that involves the engagement of individuals, groups, and organizations.
Program planning is not required in community organizing; however, it is often times used. Program planning
is a process where a health intervention is planned to meet the needs within a population. Antiviolence
campaigns and stress management courses are examples of program planning (McKenzie, Pinger, & Kotecki,
2012).
When deciding which community health interventions to create, the Centers for Disease Control and
Prevention (CDC) uses Guide to Community Preventive Services (Community Guide). The Community Guide
is considered credible because it is based off the scientific systematic review process. The guide answers
many questions that are critical to community health on subjects such as
interventions that have worked/did not work,
populations in which the intervention worked/did not work,
cost of the intervention,
benefits/risks of the intervention, and
future research recommendations (Centers for Disease Control and Prevention, 2015).
Community health programs are intricate and are a key factor in disease prevention, improving health, and
increasing quality of life. Health status and behaviors are determined by personal, environmental, policy, and
organizational influences. Community health programming is targeted at reaching the goals of Healthy People
2010. Community health programs are generally held within healthcare settings; however, other settings are
becoming more popular. Programs are being held at schools, worksites, religious organizations, and within
communities (Healthy People 2020, 2015). There are instances where healthcare organizations are
collaborating with schools to offer health programs. For instance, nutrition and exercise programs are being
offered at an increased rate. Employers see the value of employee health. Therefore, many employers offer
incentives to employees who take part in employee wellness programs. It is not far fetched to hear about
employers checking cholesterol, blood pressure, quality of life, weight, BMI, and sometimes glucose. The
rationale is that healthy employees are less likely to call in sick with health-related conditions.
Community health professionals must identify their health issue, and then create specific and measurable
goals and objectives. ...
Beyond Scaling Up: Change and complex health systemsIDS
This presentation was given at the 'Beyond Scaling Up: Pathways to Universal Access' workshop which was held at the Institute of Development Studies, Brighton on the 24-25 May, 2010. This event was co-sponsored by the Future Health Systems Research Programme Consortium and the STEPS Centre. Peters presented on change in complex health systems.
Placing the Evolution of HTA In Emerging Markets in Context of Health System ...Office of Health Economics
These slides were presented by Professor Adrian Towse at the 9th World Congress of the International Health Economics Association in July 2013. The presentation examined how the development of health care systems affect the evolution of the use of health technology assessment. Three countries provide case studies: Brazil, China and Taiwan.
Similar to HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated Health Care Decision Making in Low and Middle Income Countries (20)
On 31 October 2019, Adrian Towse and Chris Henshall from the Office of Health Economics (OHE) presented at the G20 meeting on antimicrobial drugs R&D in Paris organised by the Wellcome Trust. The topic of their presentation was HTA and payment mechanisms for new drugs to tackle antimicrobial resistance.
This presentation looks at ways in which governments can set prices, including “cost plus”, value, and the external referencing of prices elsewhere. It looks at the role that competition can play in keeping down prices. In that context it briefly discusses pricing proposals being considered in Malaysia. It makes the case for using HTA to inform pricing decisions.
Adrian Towse
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...Office of Health Economics
This presentation looks at rates of GDP spend on health care, distinguishing between categories of country (i.e. levels of GDP pre capita). It looks at the relationship between rates of spending and moves to universal health coverage, and explores alternative ways of increasing expenditure and making decisions about which services to provide with the money available.
The role of real world data and evidence in building a sustainable & efficien...Office of Health Economics
This presentation defines RWD and RWE in the context of digital health, and looks at potential uses for RWD and RWE. It briefly sets out the current landscape in Malaysia and looks at the challenges in using RWE. In particular, the issues of access, governance and ensuring good quality are considered.
The aim of this educational symposium was to discuss why we should seek value across the health care system and how we can apply existing research methods to measure the value of services. While considerable political attention in developed countries continues to be focused on drug spending, there is also growing awareness of the significant contribution of non-drug components of health care (e.g., hospital services and inefficient care delivery) to overall spending growth and patient affordability. At the same time, there is growing interest in making greater use of value assessment and value-based payment to control spending and better align it with care quality. In order to promote greater value, and to do so in ways that respond to the needs of payers and patients, it is essential to assess value across both drug- and non-drug interventions and health care services. This panel will offer expert viewpoints to identify and discuss gaps in value information, rationale and approaches to track and reduce system-wide low value care, and research methods for how to measure health care services.
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Office of Health Economics
Graham participated in an organised session on Monday July 15th 2019. In the session he presented his paper with his co-author Ioannis Laliotis from the London School of Economics. The paper revisits the relationship between workforce and maternity outcomes in the English NHS in an attempt to contribute knowledge to an important policy question for which there has been a paucity of research.
This research explores the feasibility of introducing an Outcome-Based Payment approach for new cancer drugs in England. A literature review explored the current funding landscape in England, the available evidence on existing OBP schemes internationally, and
which outcomes cancer patients value most. Two focus groups and an online survey with patients and carers, as well as interviews with NHS and government stakeholders, healthcare
professionals, and pharmaceutical industry representatives, provided additional evidence on the feasibility and suitability of OBP schemes
Understanding what aspects of health and quality of life are important to peopleOffice of Health Economics
Poster presentation from the EuroQol Plenary Meeting 2019, Brussels, Belgium. By Koonal Shah, Brendan Mulhern, Patricia Cubi-Molla, Bas Janssen, and David Mott.
Koonal presented as part of an organised session on ‘moving beyond conventional economic approaches in palliative and end of life care’. He summarised the empirical evidence on the extent of pubic support for an end of life premium, before discussing some novel approaches that have been used in recent studies. His presentation was discussed by Helen Mason of Glasgow Caledonian University.
Author(s) and affiliation(s): Koonal Shah, Office of Health Economics
Event: iHEA Congress
Date: 17/07/2019
Location: Basel, Switzerland
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Office of Health Economics
This research presented in a poster at HTAi 2019, Cologne (Germany) by a team of OHE and IHE researchers, estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden. It concludes that considering the entire life-cycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider how to measure, capture and take into account the value added by medicines over the long-run.
Author(s) and affiliation(s): Mikel Berdud (Office of Health Economics, London), Niklas Wallin-Bernhardsson (Institute for Health Economics, Stockholm), Bernarda Zamora (Office of Health Economics, London), Peter Lindgren (Institute for Health Economics, Stockholm), Adrian Towse (Office of Health Economics, London)
Event: HTAi 2019 Annual Meeting
Date: 18/06/2019
Location: Cologne, Germany
There is growing recognition that HTA and contracting systems for antimicrobials need to be adapted to help fight the threat of antimicrobial resistance (AMR), but there is little agreement on how. This poster reports findings from a literature review, expert interviews and face-to-face discussions at a Forum on the current HTA and payment systems for antibiotics across Europe and a number of recommendations for adapting these systems to respond to the challenges of AMR.
Author(s) and affiliation(s): Margherita Neri (OHE) Grace Hampson (OHE) Christopher Henshall (OHE visiting fellow, independent consultant) Adrian Towse (OHE)
Event: HTAi annual conference 2019
Date: 18/06/2019
Location: Cologne, Germany
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Office of Health Economics
This study aims to guide access decisions and drive the discussion on access and price, through recognition of the dynamic nature of value added by pharmaceutical innovation over the long-run. The analysis of the life-cycle value of risperidone estimates the value generated in the UK and Sweden. Results show that health systems were able to appropriate most of the life-cycle value generated, and this is larger than estimated at launch.
Author(s) and affiliation(s): Mikel Berdud(1), Niklas Wallin-Bernhardsson(2), Bernarda Zamora(1), Peter Lindgren(2), and Adrian Towse(1) (1) Office of Health Economics (2) The Swedish Institute for. Health Economics
Event: XXXIX JORNADAS DE ECONOMÍA DE LA SALUD
Date: 12/06/2019
Location: Albacete, Spain
Prescribed Specialised Services (PSS) Commissioning for Quality and Innovation (CQUIN) schemes were launched in 2013 in England with the aim of improving the quality of specialised care and achieving value for money. During this presentation, Marina Rodes Sanchez described the key features of the schemes and discussed its strengths and weaknesses based on international pay-for-performance literature.
Author(s) and affiliation(s): Yan Feng, Queen Mary University of London; Søren Rud Kristensen, Imperial College London; Paula Lorgelly, King’s College London; Rachel Meacock, University of Manchester; Marina Rodes Sanchez, Office of Health Economics; Luigi Siciliani, University of York; Matt Sutton, University of Manchester
Event: XXXIX Spanish Health Economics Association Conference
Date: 12/06/2019
Location: Albacete, Spain
In this session, Meng Li sets out estimates of real option value for drugs arguing that option value matters and can be calculated. Adrian Towse sets out likely payer concerns about incorporating real option value into decision making. Meng Li responds to these concerns. Jens Grueger sets out how industry considers investment opportunities, arguing that if patients (and society) have preferences these need to be reflected in P&R decisions.
Author(s) and affiliation(s): Meng Li, Postdoctoral Research Fellow, Leonard D Schaeffer Center, University of Southern California, Los Angeles, CA, USA. Adrian Towse, Emeritus Director, Office of Health Economics, London, UK Jens Grueger, formerly Head of Global Access, Senior Vice President at F. Hoffmann-La Roche
Event: ISPOR 2019
Location: New Orleans, USA
Date: 21/05/2019
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...Office of Health Economics
In this ISPOR session Chuck Phelps and Adrian Towse debated the case for and against using MCDA to support HTA decision making, as compared to weighting or augmenting a QALY based ICER approach. Chuck Phelps argued for use of MCDA, Adrian Towse for weighting the QALY. Nancy Devlin set the scene and moderated.
Author(s) and affiliation(s): Nancy Devlin, Director, Centre for Health Policy, University of Melbourne, Australia Adrian Towse, Emeritus Director, Office of Health Economics, London, UK Chuck Phelps, University of Rochester, Rochester, NY USA
Event: ISPOR 2019
Location: New Orleans, USA
Date: 21/05/2019
This presentation by Morris Kleiner (University of Minnesota), was made during the discussion “Competition and Regulation in Professions and Occupations” held at the Working Party No. 2 on Competition and Regulation on 10 June 2024. More papers and presentations on the topic can be found out at oe.cd/crps.
This presentation was uploaded with the author’s consent.
Acorn Recovery: Restore IT infra within minutesIP ServerOne
Introducing Acorn Recovery as a Service, a simple, fast, and secure managed disaster recovery (DRaaS) by IP ServerOne. A DR solution that helps restore your IT infra within minutes.
Sharpen existing tools or get a new toolbox? Contemporary cluster initiatives...Orkestra
UIIN Conference, Madrid, 27-29 May 2024
James Wilson, Orkestra and Deusto Business School
Emily Wise, Lund University
Madeline Smith, The Glasgow School of Art
0x01 - Newton's Third Law: Static vs. Dynamic AbusersOWASP Beja
f you offer a service on the web, odds are that someone will abuse it. Be it an API, a SaaS, a PaaS, or even a static website, someone somewhere will try to figure out a way to use it to their own needs. In this talk we'll compare measures that are effective against static attackers and how to battle a dynamic attacker who adapts to your counter-measures.
About the Speaker
===============
Diogo Sousa, Engineering Manager @ Canonical
An opinionated individual with an interest in cryptography and its intersection with secure software development.
Have you ever wondered how search works while visiting an e-commerce site, internal website, or searching through other types of online resources? Look no further than this informative session on the ways that taxonomies help end-users navigate the internet! Hear from taxonomists and other information professionals who have first-hand experience creating and working with taxonomies that aid in navigation, search, and discovery across a range of disciplines.
HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated Health Care Decision Making in Low and Middle Income Countries
1. 3.RESULTS
The figure shows that decision making in this way is fragmented, compartmentalised, and doesn’t follow common
objectives. This seems to be the case whether or not structured priority setting processes are used.
We also found substantial between-country variation in priority setting at all levels across LMICs: some countries have
implemented formal processes at the micro level (e.g. Thailand), whilst others have implemented major reforms at the macro
level (e.g. Rwanda). In many other LMICs, priority setting remains informal.
We identified a number of policy options and tools which could be, or have been, used to realign decision making at the
different levels in LMICs. These fall into three main categories:
1. A consistent principle of value being used to inform decision making at all levels;
2. Strengthening decision making at the disease (or intermediate) level;
3. Collecting and monitoring data on health and economic consequences of decisions at all levels.
Building Efficient Healthcare Systems
Through Integrated Health Care Decision
Making in Low and Middle Income Countries
Grace Marsden*, Martina Garau, Adrian Towse
*presenting author; email: gmarsden@ohe.org
1. INTRODUCTION
Acknowledgements
This work was funded by Novartis. The authors would like to thank Christophe Carbonel and the project team at Novartis for their input and feedback,
and thank the global health experts for participating in interviews with us.
2. METHODS
4. CONCLUSION
• Health technology assessment (HTA) and other
tools for decision making are used around the
world to promote efficient resource allocation within
healthcare systems (HCS)
• Resource allocation decisions are made at various
levels (national level or regional level; disease level
or technology level), yet it seems that the
objectives of decision makers at the different levels
do not always align with one another
• We explore whether these inconsistencies exist in
current processes in low and middle income
countries (LMICs), and identify policy options
which could be used to improve the efficiency of
resource allocation processes in these regions.
• Three strands of literature were reviewed:
1. Current approaches for priority setting in
LMICs;
2. Health service delivery and integrated care
(including disease management programmes
(DMPs));
3. Future of healthcare systems.
• Specific case studies illustrating examples of DMPs
and healthcare system reforms implemented in
LMICs were identified.
• Interviews with a set of global health experts
were conducted to gather further information on
existing priority setting processes in LMIC and the
different levels of decision making identified in the
literature review.
Micro decision making
Decision makers: Doctors, HTA
agencies, payers
Methods: HBP, HTA, A4R, MCDA,
value of implementation
Criteria: cost effectiveness, equity
Intermediate decision making
Decision makers: Payers, Providers,
Government
Methods: guidelines, protocols,
incentive schemes
Criteria: clinical outcome improvements
Macro decision making
Decision makers: Government,
insurers
Methods: Budget allocation
Criteria: equity, affordability
Service
delivery
Interventions (medical
products, vaccines and
technologies)
Payment
schemes
Health
workforce
Improved health (level and equity)
Responsiveness
Social and financial risk protection
Improved efficiency
Configuration of
facilities
Disease and
social priorities
Financing
We discuss three key levels of decision making: macro, intermediate and micro level (see figure).
Summary of levels:
different decision
makers at different
levels do not follow
common methods or
criteria
The components of the
health system:
compartmentalised and
planned at different levels
The fragmented
components are expected
to work together to
achieve these system
objectives1
Fragmentation and misalignment between levels of decision making means that decision maker’s objectives are not
consistent, and is highly likely to lead to inefficiencies in health systems.
There are limited policy options and tools available which could be used to align the objectives of decision making throughout
governments and health services. Further research is required to develop an integrated decision making framework that
could align all levels of decision making.
Notes
1The system objectives included in the diagram are those listed in the WHO building blocks framework. Full reference: WHO, 2007. Everybody’s
business: strengthening health systems to improve health outcomes: WHO's framework for action. Geneva: World Health Organization.